An Oncology Company Is Giving Away Its Old Business as a Dividend
Coherus is handing shareholders the assets it no longer wants — patents, royalties, and cell lines from its biosimilar past. The rights are non-tradeable, no buyer has been found yet, and a two-year deadline ends everything.